Small molecule · Inhibitor of histone deacetylase · developed by Syndax Pharmaceuticals
Entinostat is a synthetic benzamide derivative that inhibits histone deacetylase, an enzyme regulating chromatin structure and gene transcription. It induces dose-dependent effects including growth arrest, differentiation, reactive oxygen species generation, mitochondrial damage, and apoptosis in leukemia cells. It is studied in renal cell carcinoma and breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03501381 | Phase 2 | Renal Cell Carcinoma | Active not recruiting | SNDX |
| NCT00754312 | Phase 1 | Breast Cancer | Terminated | SNDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Renal Cell CarcinomaBreast Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the SNDX page.
See SNDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNDX catalysts and pipeline →